Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.6875
+0.01041.54%
Post-market: 0.69190.0044+0.64%19:26 EDT
Volume:3.00M
Turnover:2.07M
Market Cap:200.76M
PE:-3.45
High:0.7040
Open:0.6795
Low:0.6766
Close:0.6771
Loading ...

Ocugen Inc: Ocu400 Remains on Track to Meet 1H 2025 Recruitment Completion and Potential Bla/Maa Filings by Mid-2026

THOMSON REUTERS
·
05 Mar

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
05 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
05 Mar

Noble Financial Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
04 Mar

Ocugen Inc. Stock Slips 7.2%, Underperforms Market

Dow Jones
·
04 Mar

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

MT Newswires Live
·
04 Mar

BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification

Reuters
·
03 Mar

Ocugen Announces Positive Opinion of Ema’s Committee for Advanced Therapies for Atmp Classification for Novel Modifier Gene Therapy Candidate Ocu410 for Geographic Atrophy and Ocu410st for Stargardt Disease

THOMSON REUTERS
·
03 Mar

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

GlobeNewswire
·
03 Mar

Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)

TIPRANKS
·
02 Mar

Ocugen Inc. Stock Rises 6.8%, Outperforms Market

Dow Jones
·
01 Mar

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate Ocu410st for Stargardt Disease

THOMSON REUTERS
·
27 Feb

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

GlobeNewswire
·
27 Feb

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
25 Feb

Ocugen Inc. Stock Falls 7.4%, Underperforms Market

Dow Jones
·
25 Feb

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
22 Feb

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
21 Feb

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
19 Feb